Inventor · disambiguated record
Patrick Papa
Also filed as: PAPA PATRICK · PAPA PATRICK W · PAPA PATRICK WILLIAM
25 granted patents·15 pending applications·459 citations·filing 2007–2023
96Inventor score
Top patents by PatentIndex Score
40 records- 0198US7981893B2Heteroaryl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2007·Granted Jul 19, 2011·90 cites·10 claims
- 0296US11149007B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2019·Granted Oct 19, 2021·14 cites·41 claims
- 0396US8492381B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathwayPERRIN-NINKOVIC SOPHIE·Filed 2011·Granted Jul 23, 2013·44 cites·21 claims
- 0496US8110578B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathwayPERRIN-NINKOVIC SOPHIE·Filed 2009·Granted Feb 7, 2012·67 cites·28 claims
- 0595US8383634B2Methods of treatment using heteroaryl compounds and compositions thereofSIGNAL PHARM LLC·Filed 2011·Granted Feb 26, 2013·46 cites·4 claims
- 0695US8372976B2Methods of treatment comprising the administration of heteroaryl compoundsSIGNAL PHARM LLC·Filed 2011·Granted Feb 12, 2013·40 cites·1 claims
- 0795US7968556B2Heteroaryl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2007·Granted Jun 28, 2011·41 cites·3 claims
- 0894US11325889B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2019·Granted May 10, 2022·11 cites·35 claims
- 0993US11873283B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Jan 16, 2024·2 cites·34 claims
- 1093US8507492B2Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathwayPERRIN-NINKOVIC SOPHIE·Filed 2011·Granted Aug 13, 2013·22 cites·20 claims
- 1191US8569494B2Methods of synthesis and purification of heteroaryl compoundsHARRIS ROY L·Filed 2010·Granted Oct 29, 2013·27 cites·23 claims
- 1289US9556126B2Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2014·Granted Jan 31, 2017·10 cites·32 claims
- 1388US9771371B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2015·Granted Sep 26, 2017·4 cites·6 claims
- 1487US8299056B2Aminotriazolopyridines, compositions thereof, and methods of treatment therewithBAHMANYAR SOGOLE·Filed 2009·Granted Oct 30, 2012·22 cites·31 claims
- 1586US11919879B2Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseasesCELGENE CORP·Filed 2022·Granted Mar 5, 2024·2 cites·12 claims
- 1686US9156798B2Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2015·Granted Oct 13, 2015·5 cites·30 claims
- 1784US9079900B2Methods of synthesis and purification of heteroaryl compoundsSIGNAL PHARM LLC·Filed 2014·Granted Jul 14, 2015·5 cites·27 claims
- 1884US8907087B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2013·Granted Dec 9, 2014·4 cites·11 claims
- 1981US12404241B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2023·Granted Sep 2, 2025·0 cites·16 claims
- 2080US10167290B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2017·Granted Jan 1, 2019·1 cites·5 claims
- 2180US2023119470A1PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAYSIGNAL PHARM LLC·Filed 2022·Application pending·0 cites
- 2279US9783505B2Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2016·Granted Oct 10, 2017·2 cites·29 claims
- 2374US11292796B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2020·Granted Apr 5, 2022·0 cites·5 claims
- 2472US10683298B2Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2018·Granted Jun 16, 2020·0 cites·8 claims
- 2570US9193692B2Halogen substituted pyrazines as intermediates of mTOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2014·Granted Nov 24, 2015·0 cites·14 claims
- 2664US2024190883A1Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applicationsBIOTHERYX INC·Filed 2023·Application pending·0 cites
- 2763US12419962B2Quinazolines, pharmaceutical compositions, and therapeutic applicationsBIOTHERYX INC·Filed 2023·Granted Sep 23, 2025·0 cites·23 claims
- 2863US2025186434A1Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applicationsBIOTHERYX INC·Filed 2023·Application pending·0 cites
- 2961US2024174643A1Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applicationsBIO THERYX INC·Filed 2023·Application pending·0 cites
- 3061US2023339904A1Isoindolinones, pharmaceutical compositions, and therapeutic applicationsBIO THERYX INC·Filed 2023·Application pending·0 cites
- 3159US2024368121A1Estrogen receptor degraders, pharmaceutical compositions thereof, and their therapeutic applicationsBIOTHERYX INC·Filed 2022·Application pending·0 cites
- 3257US2024158370A1CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDSINNOVO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3356US2024124418A1Pde4 degraders, pharmaceutical compositions, and therapeutic applicationsBIOTHERYX INC·Filed 2021·Application pending·0 cites
- 3456US2024190885A1Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applicationsBIOTHERYX INC·Filed 2022·Application pending·0 cites
- 3555US2024376048A1Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative DiseasesCELGENE CORP·Filed 2022·Application pending·0 cites
- 3654US2024197888A1Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applicationsBIOTHERYX INC·Filed 2022·Application pending·0 cites
- 3754US2024025863A1Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applicationsBIOTHERYX INC·Filed 2021·Application pending·0 cites
- 3854US2024124394A1Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative DiseasesCELGENE CORP·Filed 2021·Application pending·0 cites
- 3944US2008004271A1Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewithMCKENNA JEFFREY M·Filed 2007·Application pending·0 cites
- 4043US2013005707A1Aminotriazolopyridines, compositions thereof, and methods of treatment therewithBAHMANYAR SOGOLE·Filed 2012·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →